Hennion & Walsh Asset Management’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.78M | Buy |
88,057
+2,186
| +3% | +$69.1K | 0.11% | 243 |
|
|
2025
Q1 | $2.85M | Buy |
85,871
+10,799
| +14% | +$358K | 0.13% | 205 |
|
|
2024
Q4 | $2.58M | Buy |
75,072
+20,798
| +38% | +$716K | 0.12% | 221 |
|
|
2024
Q3 | $2.17M | Buy |
54,274
+9,329
| +21% | +$373K | 0.1% | 258 |
|
|
2024
Q2 | $1.36M | Buy |
44,945
+30,638
| +214% | +$924K | 0.07% | 353 |
|
|
2024
Q1 | $480K | Sell |
14,307
-2,458
| -15% | -$82.5K | 0.03% | 577 |
|
|
2023
Q4 | $542K | Sell |
16,765
-28,130
| -63% | -$909K | 0.03% | 536 |
|
|
2023
Q3 | $1.47M | Sell |
44,895
-4,732
| -10% | -$155K | 0.09% | 266 |
|
|
2023
Q2 | $1.75M | Buy |
49,627
+516
| +1% | +$18.2K | 0.1% | 238 |
|
|
2023
Q1 | $1.6M | Buy |
49,111
+1,165
| +2% | +$38K | 0.1% | 249 |
|
|
2022
Q4 | $2.64M | Buy |
47,946
+12,090
| +34% | +$666K | 0.16% | 164 |
|
|
2022
Q3 | $1.59M | Buy |
35,856
+1,562
| +5% | +$69.2K | 0.1% | 230 |
|
|
2022
Q2 | $1.67M | Buy |
34,294
+4,575
| +15% | +$223K | 0.1% | 229 |
|
|
2022
Q1 | $1.45M | Buy |
29,719
+12,151
| +69% | +$591K | 0.08% | 272 |
|
|
2021
Q4 | $749K | Buy |
+17,568
| New | +$749K | 0.04% | 441 |
|